Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Harder S, Graff J (2013) Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol 69:1617–1633CrossRef
2.
Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, Costa J (2014) Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 100:550–556CrossRef
3.
Liakoni E, Rätz Bravo AE, Terracciano L, Heim M, Krahenbuhl S (2014) Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 174:1683–1686CrossRef
4.
Russman S, Niedrig DF, Budmiger M, Schmidt C, Stiger B, Hurlimann S et al (2014) Rvaroxaban postmarketing risk of liver injury. J Hepatol 61:293–300CrossRef
Metadata
Title
Drug-induced liver failure due to rivaroxaban
Authors
Matthew Peverelle
Khashayar Asadi
Marie Sinclair
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3364-z

Other articles of this Issue 11/2018

Annals of Hematology 11/2018 Go to the issue

Original Article

Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?

Original Article

Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network

Original Article

Effects of preemptive interferon-α monotherapy in acute leukemia patients with relapse tendency after allogeneic hematopoietic stem cell transplantation: a case-control study

Original Article

Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients

Original Article

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Case Report

Conviction in the face of affliction: a case series of Jehovah’s Witnesses with myeloid malignancies

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits